ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 16 of 45
Up
УЖМБС 2018, 3(3): 83–87
https://doi.org/10.26693/jmbs03.03.083
Clinical Medicine

Features of Left Ventricle Remodeling in Patients with Hypertension on the Primary Gout Background depending on Functional State of Kidneys

Daniuk I. O., Dotsenko S. Ya., Rekalov D. G.
Abstract

Gout is the most common cause of inflammatory arthritis in men elder 30, whose share accounts are from 0,1 % to 1,7 % of the total morbidity. An increase of the incidence of gout and its frequent association with hypertension require a detailed study of the features of heart and kidneys damage as the main target organs. The purpose of the study was to investigate the correlation between functional state of the kidneys and features of the left ventricle (LV) remodeling in patients with hypertension combined with primary gout. Material and methods. 50 men with primary gout with hypertension and 20 healthy men were investigated. We used ultrasound to detect the main morphological and functional parameters of LV. Concentration of serum uric acid, creatinine, cystatin C and the level of albuminuria were also determined. Results and discussion. In the course of study we found the significant increase of volumetric parameters of LV and significant decrease of ejection fraction on 8,3 % in patients with gout. The prevalent type of LV geometry was concentric hypertrophy (44 %). Albuminuria level significantly correlated with age of patients (R = +0,35, p < 0,05), duration of gout (R = +0,5, p < 0,05) and concentration of uric acid in serum (R = + 0,3, p < 0,05). We detected the connection between albuminuria level increasing and increasing of LV volumetric parameters, LV mass (r = +0,4, p < 0,05) and reduction of ejection fraction (r= -0,3, p < 0,05). Patients with albuminuria (n = 19) in comparison to patients without albuminuria (n = 31) were characterized by decrease of ejection fraction on 9,3 %. Moreover, there was a significant increase of LV mass on 16,3 % and index of LV mass on 20,3 % in comparison to patients without albuminuria. In patients with hypertension of the first degree the concentration of serum creatinine and level of albuminuria were not significantly different from the same parameters of the control group but cystatin C concentration was on 68,5 % higher (p < 0,001). Serum level of cystatin C correlated with ejection fraction (r= -0,3, p < 0,05) and LV mass (r = +0,4, p < 0,05). Conclusions. Patients with hypertension combined with primary gout are characterized by significant deteriorations of systolic and diastolic function of LV and prevalence of concentric hypertrophy in the remodeling structure. There is the significant correlation between albuminuria increasing and worsening of morphological and functional parameters of LV which indicate dependence of cardiovascular system from renal function. The increase in the serum level of cystatin C significantly correlates with the deterioration of the LV systolic function and begins to increase in the period of subclinical reduction of GFR and normal level of albuminuria.

Keywords: gout, hypertension, remodeling of the left ventricle, albuminuria, cystatin C

Full text: PDF (Ukr) 218K

References
  1. Dzyak GV, Homazyuk TA. Podagra: "kapkan metabolichnih problem" [Gout: "a trap of metabolic problems"]. Dnipropetrovsk: OOO "Royal print", 2010. [Ukrainian]
  2. Sirenko YuN. Gipertonicheskaya bolezn i arterialnyie gipertenzii [Hypertonic disease and arterial hypertension]. Donetsk: Izdatel Zaslavskiy 2011. [Russian]
  3. Habizhanova VB. Klinicheskie formyi uratnogo porazheniya pochek u bolnyih podagroy [Clinical forms of urate kidney damage in patients with gout]. Medicine. 2014; 10: 46-8. [Russian]
  4. Svensson-Färbom P, Ohlson Andersson M, Almgren P, Hedblad B, Engström G, Persson M, Christensson A, Melander O. Cystatin C identifies cardiovascular risk better than creatinine-based estimates of glomerular filtration in middle-aged individuals without a history of cardiovascular disease. J Intern Med. 2014; 275 (5): 506-21. https://www.ncbi.nlm.nih.gov/pubmed/24279862. https://doi.org/10.1111/joim.12169
  5. Ferri C. The problem of cardio-renal diseases in patients with gout. Curr Med Res Opin. 2017; 33: 9-13. https://www.ncbi.nlm.nih.gov/pubmed/28952391. https://doi.org/10,1080/03007995.2017.1378518
  6. Fan L, Inker LA, Rossert J, Froissart M, Rossing P, Mauer M, Levey AS. Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test. Nephrol Dial Transplant. 2014; 29 (6): 1195-203. https://www.ncbi.nlm.nih.gov/pubmed/24449101. https://www.ncbi.nlm.nih.gov/pmc/articles/4471437. https://doi.org/10.1093/ndt/gft509
  7. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Res Ther. 2015; 17: 90. https://www.ncbi.nlm.nih.gov/pubmed/25889144. https://www.ncbi.nlm.nih.gov/pmc/articles/4404569. https://doi.org/10,1186/s13075-015-0610-9
  8. Ragab G, Elshahaly M, Bardin TJ. Gout: An old disease in new perspective: a review. Adv Res. 2017; 8 (5), 495-511. https://www.ncbi.nlm.nih.gov/pmc/articles/5512152. https://doi.org/10.1016/j.jare.2017.04.008
  9. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta_analysis. Arthritis Care Res (Hoboken). 2011; 63 (1): 102-10. https://www.ncbi.nlm.nih.gov/pubmed/20824805. https://www.ncbi.nlm.nih.gov/pmc/articles/3016454. https://doi.org/10,1002/acr.20344
  10. Zamudio-Cuevas Y, Hernández-Díaz C, Pineda C, Reginato AM, Cerna-Cortés JF, Ventura-Ríos L, López-Reyes A. Molecular basis of oxidative stress in gouty arthropathy. Clin Rheumatol. 2015; 34 (10): 1667-72. https://www.ncbi.nlm.nih.gov/pubmed/25854697. https://doi.org/10,1007/s10067-015-2933
  11. Li X, Zhu H, Li P, Xin Q, Liu J, Zhang W, Xing YH, Xue HJ. Serum cystatin C concentration as an independent marker for hypertensive left ventricular hypertrophy. Geriatr Cardiol. 2013; 10 (3): 286-90.
  12. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez-Ruiz F, Mancia G. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015; 33 (9), 1729-41. discussion 1741. https://www.ncbi.nlm.nih.gov/pubmed/26136207. https://doi.org/10,1097/HJH.0000000000000701